• Recruiting

NCT04287855: Phase 2: Phase 2 Study of Isatuximab + Pomalidomide, Dex, Carfilzomib RRMM -IFM2018-03

Updated: Sep 27

IsKPd - IFM2018-03

NCT04287855: Phase 2: Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma

Isa-KPd

isa-kpd

IsKPd - IFM2018-03


Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma


Study a quadruplet-based regimen with Minimal Residual Disease (MRD) 10-5 negative rate as primary end point in patients with early Relapsed or Refractory Multiple Myeloma.


Therapeutic study, phase II, prospective, multicenter, open-label. The patients will be treated until progression. Each cycle of treatment lasts 28 days. Cycle 1 to 13 : treatment phase After cycle 13 : maintenance phase


Sponsor Poitiers University Hospital


Collaborators

Sanofi

Celgene

Amgen

Intergroupe Francophone du Myelome

 

ClinicalTrials.gov Identifier: NCT04287855


Official Title: Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma


First Posted : February 27, 2020


Click here to see details on ClinicalTrials.gov


IFM - Francophone Myeloma Intergroup (myelome.fr)

 

Drug: Isatuximab

Drug: Carfilzomib

Drug: Pomalidomide

Drug: Dexamethasone

 

Location France


Posts Archive